Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M13.7Revenue $M2.0Net Margin (%)-2,054.9Altman Z-Score-21.2
Enterprise Value $M-7.7EPS $-1.9Operating Margin %-2,054.8Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.2Pre-tax Margin (%)-2,057.2Higher ROA y-yN
Price/Book3.910-y EBITDA Growth Rate %--Quick Ratio3.0Cash flow > EarningsY
Price/Sales6.15-y EBITDA Growth Rate %--Current Ratio3.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-101.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-263.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M24.9ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ONTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ONTXGeorge Soros 2014-09-30 Sold Out $4.325 - $5.64
($5.07)
$ 0.55-89%Sold Out0
ONTXGeorge Soros 2014-06-30 Buy $4.18 - $6.22
($5.24)
$ 0.55-90%New holding10,774
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ONTX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ONTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Michael & Jane Hoffman 2013 De10% Owner 2014-02-21Buy143,480$8.47-93.51view
Hoffman Michael BDirector, 10% Owner 2014-02-21Buy143,480$8.47-93.51view
Kumar RameshPresident and CEO 2014-02-10Sell33,543$15.07-96.35view
Kumar RameshPresident and CEO 2014-02-03Sell60,000$15.05-96.35view
Hoffman Michael BDirector, 10% Owner 2014-01-27Buy57,295$11.92-95.39view
Michael & Jane Hoffman 2013 De10% Owner 2014-01-27Buy57,295$11.92-95.39view
Michael & Jane Hoffman 2013 De10% Owner 2013-11-22Buy5,000$14.39-96.18view
Hoffman Michael BDirector, 10% Owner 2013-11-22Buy5,000$14.39-96.18view
Reddy E PremkumarDirector 2013-11-18Buy5,000$12.1-95.45view
Hoffman Michael BDirector, 10% Owner 2013-11-18Buy5,000$11.87-95.37view

Quarterly/Annual Reports about ONTX:

    News about ONTX:

    Articles On GuruFocus.com
    Weekly 3-Year Low Highlights: VCRA, CLUB, ARGS, ONTX, BOTA Jun 08 2014 

    More From Other Websites
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Feb 04 2016
    Onconova Therapeutics, Inc. Announces Listing Transfer to NASDAQ Capital Market Feb 04 2016
    Onconova Therapeutics, Inc. to Present Corporate Update at the 18th Annual BIO CEO & Investor... Feb 01 2016
    Onconova Therapeutics, Inc. to Present Corporate Update at the 18th Annual BIO CEO & Investor... Feb 01 2016
    Onconova Therapeutics Announces Registered Direct Offering Jan 06 2016
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 06 2016
    Onconova Therapeutics Announces Registered Direct Offering Jan 06 2016
    Onconova Therapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 14 2015
    Onconova to Host Myelodysplastic Syndromes (MDS) Key Opinion Leader Meeting on Wednesday, December... Dec 14 2015
    Onconova to Host Myelodysplastic Syndromes (MDS) Key Opinion Leader Meeting on Wednesday, December... Dec 14 2015
    4 Small Cap NASDAQ/NYSE Stocks to Watch Today Dec 08 2015
    Why Are These Stocks Gaining Ground Today? Dec 08 2015
    ONCONOVA THERAPEUTICS, INC. Financials Dec 08 2015
    Why Onconova Is Soaring Dec 08 2015
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 08 2015
    Onconova Presents Positive Data From Phase 2 Combination Trial of Oral Rigosertib and Azacitidine in... Dec 07 2015
    Onconova Presents Positive Data From Phase 2 Combination Trial of Oral Rigosertib and Azacitidine in... Dec 07 2015
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Onconova... Dec 07 2015
    Onconova Enrolls First Patient in Phase 3 INSPIRE Trial of Rigosertib Dec 07 2015
    Onconova Enrolls First Patient in Phase 3 INSPIRE Trial of Rigosertib Dec 07 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK